特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
943515

日光角化症治療薬の世界市場:2020年-2024年

Global Actinic Keratosis Drugs Market 2020-2024

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.41円
日光角化症治療薬の世界市場:2020年-2024年
出版日: 2020年06月11日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

日光角化症治療薬市場は、2020年から2024年の間に3%のCAGRで推移し、5億2014万米ドル成長する見込みです。光線性角化症の高い有病率は、同市場の成長を後押しすると予想されます。

当レポートでは、日光角化症治療薬市場を調査し、市場概要、市場の成長要因および阻害要因の分析、タイプ別・地域別の市場規模の推移と予測、ベンダー分析、市場機会など、包括的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 2019年の市場規模
  • 市場の見通し:2019年から2024年の予測

ファイブフォース分析

ドラッグクラス別市場セグメンテーション

  • マーケット・セグメント
  • 薬物クラス別比較
  • ヌクレオシド代謝阻害剤-市場規模と予測(2019年-2024年)
  • 免疫調節剤-市場規模と予測(2019年-2024年)
  • 光増感剤-市場規模と予測(2019年-2024年)
  • NSAIDs-市場規模と予測(2019年-2024年)
  • ドラッグクラス別の市場機会

顧客情勢

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米 -市場規模と予測(2019年-2024年)
  • アジア太平洋-市場規模と予測(2019年-2024年)
  • 欧州-市場規模と予測(2019年-2024年)
  • その他の地域-市場規模と予測(2019年-2024年)
  • 主要国
  • 地域の市場機会
  • 成長要因
  • 市場の課題
  • 市場動向

ベンダー情勢

  • ベンダー情勢
  • 創造的破壊の状況

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • 3M Co.
  • Almirall SA
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Hill Dermaceuticals Inc.
  • LEO Pharma AS
  • Mylan NV
  • Nestle SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

付録

目次
Product Code: IRTNTR44052

Technavio has been monitoring the actinic keratosis drugs market and it is poised to grow by $ 520.14 mn during 2020-2024 progressing at a CAGR of 3% during the forecast period. Our reports on actinic keratosis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high prevalence of actinic keratosis and availability of combination therapy. In addition, high prevalence of actinic keratosis is anticipated to boost the growth of the market as well.

The actinic keratosis drugs market analysis includes product segment and geographical landscapes

Technavio's ‘ actinic keratosis drugs market ’ is segmented as below:

By Product:

  • Nucleoside metabolic inhibitors
  • Immunomodulators
  • Photosensitizers
  • NSAIDs

By Geography: landscapes

  • North America
  • APAC
  • Europe
  • ROW

This study identifies the threat of conversion to fatal disease as one of the prime reasons driving the actinic keratosis drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our actinic keratosis drugs market covers the following areas:

  • Actinic keratosis drugs market sizing
  • Actinic keratosis drugs market forecast
  • Actinic keratosis drugs market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading actinic keratosis drugs market vendors that include 3M Co., Almirall SA, Bausch Health Companies Inc., Biofrontera AG, Hill Dermaceuticals Inc., LEO Pharma AS, Mylan NV, Nestle SA, Novartis AG, and Sun Pharmaceutical Industries Ltd.. Also, the actinic keratosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Drug class

  • Market segments
  • Comparison by Drug class
  • Nucleoside metabolic inhibitors - Market size and forecast 2019-2024
  • Immunomodulators - Market size and forecast 2019-2024
  • Photosensitizers - Market size and forecast 2019-2024
  • NSAIDs - Market size and forecast 2019-2024
  • Market opportunity by Drug class

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume drivers - demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • 3M Co.
  • Almirall SA
  • Bausch Health Companies Inc.
  • Biofrontera AG
  • Hill Dermaceuticals Inc.
  • LEO Pharma AS
  • Mylan NV
  • Nestle SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Other1 - Market share 2019-2024 (%)
  • 22: Comparison by Other1
  • 23: Nucleoside metabolic inhibitors - Market size and forecast 2019-2024 ($ million)
  • 24: Nucleoside metabolic inhibitors - Year-over-year growth 2019-2024 (%)
  • 25: Immunomodulators - Market size and forecast 2019-2024 ($ million)
  • 26: Immunomodulators - Year-over-year growth 2019-2024 (%)
  • 27: Photosensitizers - Market size and forecast 2019-2024 ($ million)
  • 28: Photosensitizers - Year-over-year growth 2019-2024 (%)
  • 29: NSAIDs - Market size and forecast 2019-2024 ($ million)
  • 30: NSAIDs - Year-over-year growth 2019-2024 (%)
  • 31: Market opportunity by Other1
  • 32: Customer landscape
  • 33: Market share by geography 2019-2024 (%)
  • 34: Geographic comparison
  • 35: North America - Market size and forecast 2019-2024 ($ million)
  • 36: North America - Year-over-year growth 2019-2024 (%)
  • 37: APAC - Market size and forecast 2019-2024 ($ million)
  • 38: APAC - Year-over-year growth 2019-2024 (%)
  • 39: Europe - Market size and forecast 2019-2024 ($ million)
  • 40: Europe - Year-over-year growth 2019-2024 (%)
  • 41: ROW - Market size and forecast 2019-2024 ($ million)
  • 42: ROW - Year-over-year growth 2019-2024 (%)
  • 43: Key leading countries
  • 44: Market opportunity by geography ($ million)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: 3M Co. - Overview
  • 52: 3M Co. - Business segments
  • 53: 3M Co. - Key offerings
  • 54: 3M Co. - Key customers
  • 55: 3M Co. - Segment focus
  • 56: Almirall SA - Overview
  • 57: Almirall SA - Product and service
  • 58: Almirall SA - Key offerings
  • 59: Almirall SA - Key customers
  • 60: Almirall SA - Segment focus
  • 61: Bausch Health Companies Inc. - Overview
  • 62: Bausch Health Companies Inc. - Business segments
  • 63: Bausch Health Companies Inc. - Key offerings
  • 64: Bausch Health Companies Inc. - Key customers
  • 65: Bausch Health Companies Inc. - Segment focus
  • 66: Biofrontera AG - Overview
  • 67: Biofrontera AG - Product and service
  • 68: Biofrontera AG - Key offerings
  • 69: Biofrontera AG - Key customers
  • 70: Biofrontera AG - Segment focus
  • 71: Hill Dermaceuticals Inc. - Overview
  • 72: Hill Dermaceuticals Inc. - Product and service
  • 73: Hill Dermaceuticals Inc. - Key offerings
  • 74: Hill Dermaceuticals Inc. - Key customers
  • 75: Hill Dermaceuticals Inc. - Segment focus
  • 76: LEO Pharma AS - Overview
  • 77: LEO Pharma AS - Business segments
  • 78: LEO Pharma AS - Key offerings
  • 79: LEO Pharma AS - Key customers
  • 80: LEO Pharma AS - Segment focus
  • 81: Mylan NV - Overview
  • 82: Mylan NV - Business segments
  • 83: Mylan NV - Key offerings
  • 84: Mylan NV - Key customers
  • 85: Mylan NV - Segment focus
  • 86: Nestle SA - Overview
  • 87: Nestle SA - Business segments
  • 88: Nestle SA - Key offerings
  • 89: Nestle SA - Key customers
  • 90: Nestle SA - Segment focus
  • 91: Novartis AG - Overview
  • 92: Novartis AG - Business segments
  • 93: Novartis AG - Key offerings
  • 94: Novartis AG - Key customers
  • 95: Novartis AG - Segment focus
  • 96: Sun Pharmaceutical Industries Ltd. - Overview
  • 97: Sun Pharmaceutical Industries Ltd. - Business segments
  • 98: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 99: Sun Pharmaceutical Industries Ltd. - Key customers
  • 100: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.